Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03856853
Recruitment Status : Recruiting
First Posted : February 27, 2019
Last Update Posted : February 27, 2019
Sponsor:
Collaborators:
Shanghai Genomics, Inc.
GNI-EPS Pharmaceuticals, Inc. (GNI Group)
Information provided by (Responsible Party):
Beijing Continent Pharmaceutical Co, Ltd.

Brief Summary:
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Condition or disease Intervention/treatment Phase
Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) Drug: Pirfenidone Other: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Actual Study Start Date : June 15, 2018
Estimated Primary Completion Date : February 10, 2021
Estimated Study Completion Date : May 10, 2021


Arm Intervention/treatment
Experimental: treatment group
pirfenidone group
Drug: Pirfenidone
pirfenidone for SSc-ILD treatment

Placebo Comparator: placebo group
placebo group
Other: placebo
as control




Primary Outcome Measures :
  1. Relative change from baseline (%) of FVC% [ Time Frame: 52 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1.Female or male subjects aged between 18 and 75 years of age. 2.2013 ACR / EULAR classification criteria for SSc fulfilled. 3.SSc disease onset (defined by first non-Raynaud symptom) within 5 years. 4.SSc related Interstitial Lung Disease confirmed by HRCT. 5.Forced vital capacity (FVC) 40% to 70% predicted(include 40% and70% ). 6.Subject have the ability to understand and sign the informed consent before the trials.

Exclusion Criteria:

  1. Subjects not fulfill all of the above inclusion criteria.
  2. AST, ALT >1.5 x ULN.
  3. Bilirubin >1.5 x ULN.
  4. Creatinine clearance <30 mL/min.
  5. Airway obstruction (pre-bronchodilator FEV1/FVC <0.7).
  6. Other clinically significant pulmonary abnormalities.
  7. Allergic to test drugs or components (e.g. lactose).
  8. Clinical Significant Pulmonary hypertension:.

    1. Significant past clinical evidence or echocardiography of right heart failure.
    2. History of right heart catheterization showed that cardiac index ≤ 2 l/min/m2.
    3. Pulmonary hypertension, which needs to use EPoprostenol/ Treprostinil for parenteral treatment .
  9. Cardiovascular diseases:

    1. Six weeks in severe hypertension, and out of control after treatment(≥160/100mmHg).
    2. Myocardial infarction within six months.
    3. A period of 6 months in unstable angina.
  10. More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers.
  11. Bleeding risk, including the following criterias:

    a. Predisposition to bleeding. b.Subjects need to the following treatments: i.Fibrinolysis, full-dose anticoagulation therapy(such as vitamin K antagonists, direct thrombin inhibitor, heparin, Hirudin ).

    ii. High dose antiplatelet therapy[Note: not prohibited to maintain equipment needed indwelling venous pathway prophylactic low dose of heparin or heparin fluid (e.g. enoxaparin, daily 4000 I.U. s.c.) and the prevention of the use of antiplatelet therapy (e.g. acetylsalicylic acid, until 325 mg/d, or other antiplatelet dose of 75 mg/d the same dose of clopidogrel, or treatment)].

    c.history of hemorrhagic central nervous system (CNS) event within last year. d. Any of the following conditions within 3 months: i.Hemoptysis or hematuria ii. Active gastrointestinal bleeding or gastrointestinal ulcer. iii. major trauma or major surgery (researchers determined). e.coagulation parameters:international normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN)

  12. May interfere with detection procedures (such as interrupt oxygen intolerance in pulmonary function tests) or based on the researchers estimate, may affect the test to participate in or participate in the test may put patients at risk of disease or other complications (such as caused by SSc severe gastrointestinal symptoms).
  13. Researchers determined that life expectancy was due to other diseases (non SSc) for a period of up to 2.5 years.
  14. Clinical signs of malabsorption or needing parenteral nutrition.
  15. History of thrombotic event within last year(Including stroke and transient ischemic attack).
  16. Previous treatment with nintedanib or pirfenidone.
  17. Use the following medicine:

    1. Treatment with prednisone >10 mg/day within 2 weeks.
    2. Treatment with azathioprine, hydroxychloroquine, colchizine, D-penicillamine, sulfasalazine within 8 weeks .
    3. Treatment with cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and ciclosporine A, potassium para-aminobenzoate within 6 months.
  18. Unstable background therapy with cyclophosphamide or mycophenolate mofetil / sodium or methotrexate (not allow treatment). Patients must or A. patients cannot receive immunosuppressive therapy, sodium cyclophosphamide or mycophenolate mofetil / or MTX stable or B. within 6 months of acceptance, and in at least 6 months after randomization, the treatment to keep the background stable (exclusion criteria 16 and 17 and the combined use of early precautions).
  19. Previous or planned hematopoietic stem cell transplantation next year.
  20. Major surgery is planned during the treatment period.
  21. Pregnancy or lactation or make a schedule during the trials.
  22. Give the drug 28 days before or after administration of the 3 month period, women of childbearing age * are unwilling or unable to use contraceptive methods highly effective (according to ICH M3 (R2)), a highly effective means in the correct and consistent application of a barrier method when the failure rate of less than 1% per year. * women of childbearing age is defined has undergone menarche and in line with "infertile women" standard "[female infertile women" is defined as: postmenopausal period (12 months without menstruation, no other medical reasons) or permanent sterilization (e.g., tubal occlusion, hysterectomy, bilateral ovarian resection or bilateral tubal resection women)].

(23)According to the researchers,exhibited evidence of alcohol or drug abuse. (24)Patients who were unable to understand or comply with the procedure were included in the self-administered questionnaire, which was completed without help.

25.Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment).

26.Clinical signs of malabsorption or needing parenteral nutrition. 27.With active peptic ulcer. 28.With mental illness . 29.Within 3 months to participate in other clinical trials. 30.Researchers determined that they did not participate in the trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03856853


Locations
Layout table for location information
China, Beijing
Zhang, Ling Recruiting
Beijing, Beijing, China, 100102
Contact: Ling Zhang    +86-13501209210    rlzhang1006@163.com   
Contact: Qian Wang    +86-13681211155    zhengaqian@icloud.com   
Sponsors and Collaborators
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.
GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Layout table for additonal information
Responsible Party: Beijing Continent Pharmaceutical Co, Ltd.
ClinicalTrials.gov Identifier: NCT03856853     History of Changes
Other Study ID Numbers: GNI-F647-1701
First Posted: February 27, 2019    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Lung Diseases
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Connective Tissue Diseases
Skin Diseases
Pirfenidone
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents